Jean-Pierre Garnier elected chairman of Actelion
pharmafile | October 3, 2011 | Appointment | Sales and Marketing | appointment, sales and marketing
Jean-Pierre Garnier has been elected chairman of Swiss biopharmaceutical company Actelion.
He has sat on the company’s board since May and as chairman takes over from Robert Cawthorn, who had held the role since the company’s foundation in 1997.
Jean-Pierre Garnier was the first chief executive of GlaxoSmitKline, a position he held for seven years, and prior to the merger that created that company he served at SmithKline Beecham in a variety of senior roles.
Commenting on his new appointment Jean-Pierre said: “I’m very impressed with the company’s track record and its position today as Europe’s largest biopharmaceutical company.
“Since joining the company this spring, I have become even more convinced of Actelion’s capacity to translate superior drug discovery into meaningful therapeutic solutions and long-term business success.”
Actelion has operations in more than 25 countries and its products include the hypertension brand Tracleer and Gaucher disease treatment Zavesca.
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






